<?xml version="1.0" encoding="UTF-8"?>
<p>KJ and MH work for Cilian which developed the ciliate platform and has a commercial interest. BV and CP work for Adjuvatis which owns the adjuvant platform and have a commercial interest. Both of these parties supplied material and were not involved in data analysis or interpretation. EM works for Vismederi srl, which analyses responses influenza vaccines and infection, Vismederi analyzed data from the project. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
